Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination

Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination

Rationale The pathophysiology of most lacunar stroke, a form of small vessel disease, is thought to differ from large artery atherothrombo- or cardio-embolic stroke. Licensed drugs, isosorbide mononitrate and cilostazol, have promising mechanisms of action to support their testing to prevent stro...

Full description

Bibliographic Details
Main Authors: Blair, Gordon W., Appleton, Jason P., Law, Zhe Kang, Doubal, Fergus, Flaherty, Katie, Dooley, Richard, Shuler, Kirsten, Richardson, Carla, Hamilton, Iona, Shi, Yulu, Stringer, Michael, Boyd, Julia, Thrippleton, Michael J., Sprigg, Nikola, Bath, Philip M.W., Wardlaw, Joanna M.
Format: Article
Published: Sage 2018
Subjects:
Lacunar stroke
Small vessel disease
Cilostazol
Isosorbide mononitrate
Endothelium
Blood–brain barrier
White matter hyperintensities
Cerebrovascular reactivity
Online Access:https://eprints.nottingham.ac.uk/47047/

Internet

https://eprints.nottingham.ac.uk/47047/

Similar Items